Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Randomized Master Protocol for Immune Modulators for Treating COVID-19

Next Previous
Trial Profile

Randomized Master Protocol for Immune Modulators for Treating COVID-19

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 02 Dec 2024

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Abatacept (Primary) ; Cenicriviroc (Primary) ; Infliximab (Primary) ; Dexamethasone; Remdesivir
  • Indications COVID 2019 infections; COVID-19 pneumonia; SARS-CoV-2 acute respiratory disease
  • Focus Therapeutic Use
  • Acronyms ACTIV-1 IM

Most Recent Events

  • 10 Jul 2023 Results investigating whether abatacept, cenicriviroc, or infliximab provides benefit when added to standard care for COVID-19 pneumonia , published in the JAMA: the Journal of the American Medical Association
  • 02 Jun 2022 Results presented in a Bristol-Myers Squibb Media Release.
  • 02 Jun 2022 According to a Bristol-Myers Squibb media release, the full report on these data will be published in a peer-reviewed scientific journal. Given the positive findings from the topline data, Bristol Myers Squibb plans to discuss these data and potential next steps with the U.S. Food and Drug Administration.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top